Taro Pharmaceutical Industries (NYSE:TARO) posted its earnings results on Thursday. The company reported $1.71 EPS for the quarter, missing the Zacks’ consensus estimate of $2.33 by ($0.62), Fidelity Earnings reports. Taro Pharmaceutical Industries had a net margin of 31.90% and a return on equity of 11.33%. The company had revenue of $154.62 million during the quarter, compared to analyst estimates of $179.54 million.
NYSE TARO opened at $106.89 on Friday. Taro Pharmaceutical Industries has a 12 month low of $93.01 and a 12 month high of $128.46. The stock has a market capitalization of $4.48 billion, a price-to-earnings ratio of 17.30 and a beta of 0.50.
A number of research analysts have commented on TARO shares. HC Wainwright set a $124.00 target price on shares of Taro Pharmaceutical Industries and gave the company a “buy” rating in a research report on Tuesday, May 15th. Zacks Investment Research raised shares of Taro Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $129.00 target price on the stock in a research report on Saturday, May 26th. Finally, TheStreet raised shares of Taro Pharmaceutical Industries from a “c+” rating to a “b-” rating in a research report on Monday, June 4th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Taro Pharmaceutical Industries has an average rating of “Buy” and a consensus target price of $124.50.
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
See Also: Google Finance Portfolio
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.